Track topics on Twitter Track topics that are important to you
In this exclusive interview, Fintan Walton talks to Ben Cons, Vice President of NovaQuest, about NovaQuest’s functions and operations, and how these differ from those of its parent company, Quintiles Transnational. Ben talks about the financial commitment NovaQuest has made to its partnerships and how this is split between its biotech and large pharma clients. He outlines the two principle ways in which NovaQuest operates with companies, and how it shares some of the risks and returns. Ben discusses the current changes in the industry, the drivers for these changes, and how they affect NovaQuest’s business. He highlights some examples of partnerships that show how the company is adapting to these changes – in particular he discusses its alliances with Eli Lilly and Solvay Pharmaceuticals. Ben talks about how NovaQuest manages the risk within its alliance portfolio and the company’s approach to its equity contributions in life sciences companies. Finally, he gives his opinion on the progress of the industry from NovaQuest’s viewpoint, and discusses how the company will grow in relation to Quintiles.
Original Article: NovaQuest: Principles and StrategiesNEXT ARTICLE
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...